Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT00378196
Phase
PHASE1
Status
Completed

Conditions

  • Telangiectasia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.

Key Dates

First listed
Sep 19, 2006
Start date
Sep 30, 2006
Status verified
Nov 2012
Primary completion
Sep 30, 2007
Completion
Dec 31, 2008

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    0.3 mg/0.05 ml dose of ranibizumab
  • Experimental: B
    0.5 mg /0.05 ml dose of ranibizumab

Primary Outcome Measure

Proportion of subjects with improvement of 15 or more letters of best corrected visual acuity from baseline to 3 months on an Early Treatment Diabetic Retinopathy visual acuity chart measured at 4 meters [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Wilmer Eye Institute at Johns HopkinsBaltimoreMaryland21287-

Find similar trials in Baltimore, MD

By research site
The Wilmer Eye Institute at Johns Hopkins· Baltimore, MD

Related Studies